Ritter CA - Search Results

1

Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics.

Reyzer ML, Caldwell RL, Dugger TC, Forbes JT, Ritter CA, Guix M, Arteaga CL, Caprioli RM. Reyzer ML, et al. Among authors: ritter ca. Cancer Res. 2004 Dec 15;64(24):9093-100. doi: 10.1158/0008-5472.CAN-04-2231. Cancer Res. 2004. PMID: 15604278

2

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Yakes FM, et al. Among authors: ritter ca. Cancer Res. 2002 Jul 15;62(14):4132-41. Cancer Res. 2002. PMID: 12124352

3

Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model.

Ritter CA, Bianco R, Dugger T, Forbes J, Qu S, Rinehart C, King W, Arteaga CL. Ritter CA, et al. Int J Clin Pharmacol Ther. 2004 Nov;42(11):642-3. doi: 10.5414/cpp42642. Int J Clin Pharmacol Ther. 2004. PMID: 15598031 No abstract available.

4

Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.

Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL. Muraoka RS, et al. Among authors: ritter ca. J Clin Invest. 2002 Jun;109(12):1551-9. doi: 10.1172/JCI15234. J Clin Invest. 2002. PMID: 12070302 Free PMC article.

5

The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.

Ritter CA, Arteaga CL. Ritter CA, et al. Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11. doi: 10.1053/sonc.2003.50027. Semin Oncol. 2003. PMID: 12644979 Review.

6

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.

Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL. Ritter CA, et al. Clin Cancer Res. 2007 Aug 15;13(16):4909-19. doi: 10.1158/1078-0432.CCR-07-0701. Clin Cancer Res. 2007. PMID: 17699871

7

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.

Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL. Bianco R, et al. Among authors: ritter ca. Oncogene. 2003 May 8;22(18):2812-22. doi: 10.1038/sj.onc.1206388. Oncogene. 2003. PMID: 12743604

8

The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.

Bien S, Riad A, Ritter CA, Gratz M, Olshausen F, Westermann D, Grube M, Krieg T, Ciecholewski S, Felix SB, Staudt A, Schultheiss HP, Ewert R, Völker U, Tschöpe C, Kroemer HK. Bien S, et al. Among authors: ritter ca. Cancer Res. 2007 Nov 1;67(21):10428-35. doi: 10.1158/0008-5472.CAN-07-1344. Cancer Res. 2007. PMID: 17974986

9

Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival.

Guo Y, Köck K, Ritter CA, Chen ZS, Grube M, Jedlitschky G, Illmer T, Ayres M, Beck JF, Siegmund W, Ehninger G, Gandhi V, Kroemer HK, Kruh GD, Schaich M. Guo Y, et al. Among authors: ritter ca. Clin Cancer Res. 2009 Mar 1;15(5):1762-9. doi: 10.1158/1078-0432.CCR-08-0442. Epub 2009 Feb 24. Clin Cancer Res. 2009. PMID: 19240178 Free PMC article. Clinical Trial.

10

Modulation of the cellular toxicity of nitrogen mustard in murine cells.

Ritter C, Rutman RJ, Goldstein NO. Ritter C, et al. Cancer Res. 1987 Jan 15;47(2):472-6. Cancer Res. 1987. PMID: 3791235

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

95 results

Search Page